Subscribe to NRx Newsletter

Investor Relations

NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor. Please click here for more on our clinical trial status.

NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.

Stock Data

NRX Pharmaceuticals Inc. (NRXP)
Detailed Quote

Recent News

Recent News (new)

For more news and articles, visit our news page.

Press Release
February 20, 2024

HOPE shares currently owned by NRXP with planned share dividend to existing NRXP shareholders HOPE has now completed initial manufacture of Ketamine for IV infusion and plans to file FDA New Drug...

Press Release
February 12, 2024

Companies continue to work collaboratively to advance NRX-101 through registrational trials NRx remains eligible for an additional $324 million in development and sales milestones, as well as...

Press Release
February 9, 2024

Companies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its...

Bottom Global Links (above footer)
NRx Communications

Subscribe to the NRx Mailing List